SGLT-2 inhibitors

Phase 3Small molecule

Novo Nordisk

SGLT-2 inhibitors is one of 38 small molecule programs targeting Ischemic stroke. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Ischemic StrokeNot yet recruiting

Ischemic StrokePhase 3

Not yet recruiting

Competition

Competitive Landscape

116 competitors in Ischemic Stroke

#DrugCompanyPhaseTrials

Tnkase

Roche

Phase 3

17 2

Ozempic

Novo Nordisk

Phase 3

3 3

Atorvastatin Calcium

Merck & Co.

Phase 3

1 4

Butylphthalide

PPeking Union Medical College Hospital

Phase 3

3 5

PCSK9 Inhibitor

YYun Dai Chen

Phase 3

3 6

Edaravone Dexborneol

SSimcere Pharmaceutical Co., Ltd

Phase 3

9 7

Tenecteplase or Alteplase

IInsel Gruppe AG, University Hospital Bern

Phase 3

2 8

SGLT-2 inhibitors

Novo Nordisk

Phase 3

1 9

Proamatine

Takeda

Preclinical

2 10

Levaquin

WWim Janssens

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Recruiting

Paroxysmal Atrial Fibrillation

NCT07482020

Q4 2028

Phase 2Recruiting

STEMI

NCT05305911

Clinical

Trials by Indication[1]

STEMI1 trial

Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI

Recruiting·MMinneapolis Heart Institute Foundation·Phase 2·NCT05305911·81 enrolled

Type 2 Diabetes1 trial

Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 4·NCT02730377·1,991 enrolled

Paroxysmal atrial fibrillation1 trial

SGLT2i Improve Left Atrial Function in Patients With Paroxysmal Atrial Fibrillation, Hypertension and Abnormal Glucose Metabolism

Recruiting·HHuashan Hospital·Phase 2·NCT07482020·66 enrolled

Ischemic stroke1 trial

SLGT2i for Neuroprotection in Patients With Acute Ischemic Stroke

Not yet recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 3·NCT07105917·1,050 enrolled

Unspecified1 trial

SGLT2-inhibitors on PC-AKI

Active, not recruiting·SShenyang Northern Hospital··NCT06491953·3,600 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for SGLT-2 inhibitors. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SGLT-2 inhibitors compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SGLT-2 inhibitors. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novo Nordisk company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Novo Nordisk

SGLT-2 inhibitors

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q4 2028

Trials by Indication[1]

STEMI1 trial

Type 2 Diabetes1 trial

Paroxysmal atrial fibrillation1 trial

Ischemic stroke1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News